-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – XLRN-517 in Chronic Urticaria Or Hives
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - XLRN-517 in Chronic Urticaria Or Hives report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. XLRN-517 in Chronic Urticaria Or Hives Drug Details: XLRN-517...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – Seralutinib in Pulmonary Arterial Hypertension
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - Seralutinib in Pulmonary Arterial Hypertension report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. Seralutinib in Pulmonary Arterial Hypertension Drug Details: Seralutinib is under...
-
Company Insights
NewArrayit Corp Pipeline Insight and Competitive Landscape, 2024
Empower your strategies with our Arrayit Corp Pipeline Insight and Competitive Landscape, 2024 report and make more profitable business decisions. Arrayit Corp engaged in research, developing and manufacturing proprietary life science and personalized medicine products. Its products include microarray scanners, microarrayers, deoxyribonucleic acid (DNA) microarrays, protein microarrays, microarray printing, microarray instruments, microarray substrate slides amplification and labeling kits and purification kits. It provides diagnostic services, patient data solutions, fingerstick allergy testing services and reimbursement support services. The company serves to...
-
Company Insights
NewGenetic Analysis AS Pipeline Insight and Competitive Landscape, 2024
Empower your strategies with our Genetic Analysis AS Pipeline Insight and Competitive Landscape, 2024 report and make more profitable business decisions. Genetic Analysis AS (Genetic Analysis) is a molecular diagnostic company that mapping of microbiota by utilizing the GA-map technology to develop IVD tests in various diseases. Its products include service products and lab products. Service and lab products include dysbiosis test Lx reagent kit, Covid-19 fecal test reagent kit. It offers services include research and diagnostics, companion diagnostics, laboratory...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – NMS-088 in Refractory Acute Myeloid Leukemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - NMS-088 in Refractory Acute Myeloid Leukemia report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. NMS-088 in Refractory Acute Myeloid Leukemia Drug Details: NMS-088...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – NMS-088 in Relapsed Acute Myeloid Leukemia
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - NMS-088 in Relapsed Acute Myeloid Leukemia report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. NMS-088 in Relapsed Acute Myeloid Leukemia Drug Details: NMS-088...
-
Product Insights
NewLikelihood of Approval and Phase Transition Success Rate Model – NMS-088 in Chronic Myelomonocytic Leukemia (CMML)
Empower your strategies with our Likelihood of Approval and Phase Transition Success Rate Model - NMS-088 in Chronic Myelomonocytic Leukemia (CMML) report and make more profitable business decisions. This report provides you with the data that allows you to track and predict the specific likelihood of approval (LOA) and phase transition success rate (PTSR) of a drug using GlobalData’s proprietary machine learning algorithms developed using over 10 years of historical data. NMS-088 in Chronic Myelomonocytic Leukemia (CMML) Drug Details: NMS-088...
-
Product Insights
NewOasis Diagnostics Corp Pipeline Insight and Competitive Landscape, 2023
Empower your strategies with our Oasis Diagnostics Corp Pipeline Insight and Competitive Landscape, 2023 report and make more profitable business decisions. Oasis Diagnostics Corp (Oasis Diagnostics) is a medical device company that develops and commercializes tools for non-invasive diagnosis and detection of diseases. The company's products include saliva DNA isolation kit, genomic kit and immunoassay products,. Its saliva DNA isolation kit provides salivary DNA collection device, oral fluid collection system, saliva collection device and split sample saliva collection device. Oasis...
-
Sector Analysis
NewBusiness of the National Women’s Soccer League (NWSL) 2024 – Property Profile, Sponsorship and Media Landscape
National Women’s Soccer League (NWSL) 2024 Report Overview The estimated sponsorship revenue of the National Women’s Soccer League (NWSL) is $25.5 million for the 2024 season through 11 active sponsorship deals. A major shift in the media rights landscape has begun in 2024, with four major partners agreeing to terms for exclusive coverage in the US. These deals are effective between the 2024 and 2027 seasons. The National Women’s Soccer League (NWSL) 2024 report provides an overview of the National...
-
Company Insights
NewBio-Techne Corp Pipeline Insight and Competitive Landscape, 2024
Empower your strategies with our Bio-Techne Corp Pipeline Insight and Competitive Landscape, 2024 report and make more profitable business decisions. Bio-Techne Corp (Bio-Techne) manufactures, develops and markets biotechnology products and scientific tools to understand biological processes and drive research. The company’s product portfolio includes ELISA kits, ELISpot kits, enzymes, Luminex assays, proteins, GMP products and instruments. Its custom service offerings comprise antibody services, targeted protein degradation services, licensing, cell and gene therapy services, compound library services, ELISA services and gene...